FDA authorizes Amgen, Wyeth rheumatoid arthritis treatment

09/29/2004 | Forbes

The companies said their jointly developed Enbrel, administered in pre-filled syringes, is the first biologic to induce a major clinical response in victims of the disease, helping physicians measure improvement over a six-month period. The companies said they also got approval for new data on the treatment's effectiveness to be included in Enbrel labeling.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Behavioral Health Operations
Meridian Health Plan
Detroit, MI
Medical Director
PacificSource
Bend, OR
Clinical Appeals RN
MJHS
Brooklyn, NY
Director of Clinical Operations
Meridian Health Plan
Detroit, MI
Sr. Director, Regulatory Compliance Intelligence and Outreach
Johnson & Johnson
New Brunswick, NJ